Hanmi Pharmaceutical

Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Mercoledì, Aprile 24, 2024
MSD, FDA, Clinical trial, BJHM, Safety, AI, Neutropenia, Merck & Co., Pembrolizumab, Innovation, Tumor microenvironment, PD-L1, Obesity, Hanmi Pharmaceutical, Patient, Principal, KOSPI, Drug development, Merck, MASH, TME, Pharmaceutical industry

SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA).

Key Points: 
  • Upon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to evaluate the safety and efficacy of its immuno-oncology drug, 'BH3120', in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with progressive or metastatic solid tumors.
  • Hanmi Pharmaceutical will sponsor the clinical trial, and MSD will supply KEYTRUDA.
  • 'BH3120' is a next-generation immunotherapy drug that applies 'Pentambody', a bispecific antibody platform technology, currently under joint development by Hanmi Pharmaceutical and its Chinese subsidiary, BJHM (Beijing Hanmi Pharmaceutical).
  • He said, "Through the collaboration with MSD, we expect BH3120 in combination with KEYTRUDA could improve outcomes for patients with relapsed or refractory disease."

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Martedì, Marzo 26, 2024
Indian stock exchange, Absorption, Plasma, Exercise, Hanmi Pharmaceutical, AML, BID, Patient, APS, SAN, Venetoclax, G1, VEN, FLT3, EHA, LUX, Acute myeloid leukemia, Trial of the century, TUS, TSX, Hanmi, Azacitidine, G3, Pharmaceutical industry

This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.

Key Points: 
  • This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.
  • Total gross proceeds from the public offering were approximately $9.7 million before deducting underwriting costs, placement agent commissions and other offering-related expenses.
  • Private Placement – On January 31, 2024, Aptose closed a US $4 million private placement of common shares with strategic partner Hanmi Pharmaceutical.
  • Luxeptinib G3 Evaluation Completed – During 2023 and early 2024, clinical evaluation of the new generation 3 (G3) formulation of luxeptinib (LUX) was completed.

"Double Life" of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune Diseases

Retrieved on: 
Venerdì, Marzo 8, 2024
Bangladesh Technical Education Board, University of Oslo, Cancer, University, The central science, Immune system, Research, Doctor of Philosophy, Science Immunology, National Institutes of Health, MD, Moses Austin, Neoplasm, Inflammation, Wang, Wellcome Trust, Rheumatology, Lupus, PD-1, Bristol Myers Squibb, Howard Hughes Medical Institute, Biochemistry, NYU, Autoimmunity, Perlmutter, Rheumatoid arthritis, Pathology, Ligand, Pharmacology, NYU Langone Health, Patient, Hanmi Pharmaceutical, Internal medicine, Biomedical sciences, Funding of science, Columbia University, Mouse, Vaccine

The same findings also support experimental treatment strategies for autoimmune diseases, in which the immune system attacks the body, because stimulating the action of PD-1, as opposed to restricting it, can potentially block an overactive immune response.

Key Points: 
  • The same findings also support experimental treatment strategies for autoimmune diseases, in which the immune system attacks the body, because stimulating the action of PD-1, as opposed to restricting it, can potentially block an overactive immune response.
  • The study results revolve around the body's immune system, which is primed to attack virally infected and cancerous cells while leaving normal cells alone.
  • The immune system recognizes tumors as abnormal, but cancer cells can hijack checkpoints to turn off immune responses.
  • At the same time, PD-1 signaling is slowed in autoimmune diseases like rheumatoid arthritis, lupus, and type 1 diabetes, such that the action of unchecked immune cells creates inflammation that can damage tissues.

GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024

Retrieved on: 
Mercoledì, Febbraio 14, 2024
Enzyme replacement therapy, Fabry disease, ICV, EMA, Intelligence, European, Glycolipid, ERT, Sanfilippo syndrome, Hunter syndrome, Death, MPS, Prevalence, ODD, Safety, Sanfilippo, IDS, Disorder, Patient, Hanmi Pharmaceutical, Fibrosis, Clinical trial, Knowledge, Kidney disease, Disease, Urine, Heart, Alpha-galactosidase, Phase, Male, Kidney, Glycogen storage disease, Brain, Orphan, Mouse, Pharmaceutical industry

YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024 in San Diego, USA.

Key Points: 
  • YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024 in San Diego, USA.
  • WorldSymposium 2024 is an international forum for Lysosomal Diseases experts to share and exchange insights for researching better treatment of the disease.
  • In 2012, GC Biopharma succeeded in developing the world's second treatment for Hunter syndrome, "Hunterase" solely using domestic technology.
  • GC Biopharma, together with Hanmi Pharmaceutical, is developing GC1134A/HM15421, a long-acting alpha-galactosidase that can be administered subcutaneously once a month to improve patient convenience.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on: 
Lunedì, Gennaio 8, 2024
Editorial, Diabetes, Risk, CER, Fatty liver disease, Health, Nausea, Tissue, Heart, Cancer, Inflammation, Patent, Ageing, Obesity, Crohn's disease, Liver disease, LEXX, NVO, Invention, DSM-IV codes, Parkinson's disease, Pfizer, Kidney disease, Paratriathlon, European, Disease, Alzheimer's disease, Pharmacokinetics, Bone density, Merck, Facial muscles, Human, Safety, Pharma, MRK, Addiction, SNAC, AstraZeneca, PFE, DKK, Blood, Mouth, Novo Nordisk, Vomiting, Autoimmune disease, Research, Diarrhea, Weight loss, Hanmi Pharmaceutical, Weapon, Clinical trial, Refrigeration, Chronic kidney disease, Growth, Pharmaceutical industry

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points: 
  • GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
  • Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
  • Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on: 
Lunedì, Gennaio 8, 2024
Editorial, Diabetes, Risk, CER, Fatty liver disease, Health, Nausea, Tissue, Heart, Cancer, Inflammation, Patent, Ageing, Obesity, Crohn's disease, Liver disease, LEXX, NVO, Invention, DSM-IV codes, Parkinson's disease, Pfizer, Kidney disease, Paratriathlon, European, Disease, Alzheimer's disease, Pharmacokinetics, Bone density, Merck, Facial muscles, Human, Safety, Pharma, MRK, Addiction, SNAC, AstraZeneca, PFE, DKK, Blood, Mouth, Novo Nordisk, Vomiting, Autoimmune disease, Research, Diarrhea, Weight loss, Hanmi Pharmaceutical, Weapon, Clinical trial, Refrigeration, Chronic kidney disease, Growth, Pharmaceutical industry

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points: 
  • GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
  • Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
  • Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Successful Launch of JVM's Next-Generation Automated Drug Dispensing System via High-End Robot Arm 'MENITH' in the European Market

Retrieved on: 
Lunedì, Ottobre 16, 2023
Online, Pharmacy, JVM, Hanmi Pharmaceutical, Development, Plasma protein binding, Automation, Soft drink

SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.

Key Points: 
  • SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.
  • Based on this contract, JVM will be able to expand its European business, which had been focused on entry-level models, to 'large-scale high-end models'.
  • MENITH is one of JVM's next-generation products that will lead the future pharmacy automation market.
  • It is also equipped with an automated inspection system, which minimizes the pharmacy dispensing process time and resources.

SHAREHOLDER ALERT: Morris Kandinov Investigating EBS, JRVR, EGIO, and HAFC; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Mercoledì, Settembre 20, 2023
Hanmi, Emergent BioSolutions, Johnson & Johnson, Akamai Techs., Inc. v. Limelight Networks, Inc., Central District, Hanmi Pharmaceutical, COVID-19, Emergent, History, AstraZeneca, Public sector banks in India, Complaint, District court, Settlement, Edgio, Advertising, SAN, Growth, Bacteria, FDA, Pharmaceutical industry

Morris Kandinov is investigating Emergent BioSolutions Inc. regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.

Key Points: 
  • Morris Kandinov is investigating Emergent BioSolutions Inc. regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Morris Kandinov reminds investors that it is investigating James River Group Holdings regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Morris Kandinov reminds investors that it is investigating Hanmi Financial Corporation regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Concerned shareholders are encouraged to contact Leo Kandinov to learn more:
    Morris Kandinov LLP is a national law firm that specializes in recovering investment losses and protecting stockholder rights.

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

Retrieved on: 
Mercoledì, Settembre 6, 2023
TP53, Toronto Stock Exchange, TUS, Hope, Mutation, Consultant, Acute myeloid leukemia, AML, Hanmi Pharmaceutical, Patient, SAN, FLT3, TSX, Safety, Pharmaceutical industry, Security (finance), Hanmi, Share (finance)

Under the terms of the strategic investment, Hanmi purchased each Share at a price of $4.488, representing a premium over Aptose’s common stock price.

Key Points: 
  • Under the terms of the strategic investment, Hanmi purchased each Share at a price of $4.488, representing a premium over Aptose’s common stock price.
  • Aptose has granted Hanmi certain rights pursuant to an investor rights agreement, including registration rights, pre-emptive rights, information rights and the right to appoint non-executive consultants.
  • The closing of the second tranche for up to $4 million or a maximum of 19.99 percent ownership interest will be triggered upon Aptose achieving, prior to July 1, 2024, certain manufacturing and data milestones related to tuspetinib.
  • “We are grateful to our valued partner Hanmi Pharmaceutical for this investment and their confidence in our strategic direction," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

SHAREHOLDER ALERT: Morris Kandinov Investigating FATE, HAFC, PEGA, and CVNA; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Lunedì, Agosto 21, 2023
Hanmi, Central District, Hanmi Pharmaceutical, Public sector banks in India, Complaint, Destiny, District court, Settlement, SAN, Therapy, Pharmaceutical industry, Carvana

Morris Kandinov is investigating Fate Therapeutics, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.

Key Points: 
  • Morris Kandinov is investigating Fate Therapeutics, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Hanmi Financial Corporation regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Pegasystems regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Morris Kandinov is investigating Carvana Co. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.